Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)

NCT01451437 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

26

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early due to business reasons.

Conditions

Acute Myelogenous Leukemia (AML)

Interventions

DRUG: MK-8242

Sponsor

Merck Sharp & Dohme LLC